Preview of the New NHLBI Guidelines for the
Diagnosis and Management of Asthma
Faculty Disclosure Statements

Don Bukstein, MD has disclosed that he has received payment or service of an amount from a commercial or other party related directly to the subject of his presentation. Grant information and company names appear as provided by the speaker.

Dr. Bukstein has been awarded educational grants and has taken part in professional activities with AstraZeneca, Aventis, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer and Schering. The professional activities he has been involved with include: clinical research, educational programs, scientific consultant, and speaker's bureaus. Dr. Bukstein and his family members do not have a significant financial interest in any of these companies or others that could represent a commercial or personal conflict of interest. He has received consultant fee, honoraria, and educational grants for patients and physicians from the above companies totaling over $10,000 in the past five years.

Allen Goldberg, MD has disclosed no significant relationships with the companies/organizations whose products or services may be discussed within this presentation.

Allan Luskin, MD has disclosed that he has received payment or service of an amount from a commercial or other party related directly to the subject of his presentation. Grant information and company names appear as provided by the speaker.

Consultant/Advisory Board (all more than $5,000): Merck, Genentech, Novartis Pharmaceuticals, Schering-Plough, 3M Pharmaceuticals, Abbot Laboratories, Sanofi-Aventis, AstraZeneca, Critical Therapeutics, Aerocrine, TEVA Pharmaceutics, King Pharmaceuticals, IVAX

Research Support: Merck, AstraZeneca, Sanofi-Aventis, Novartis Pharmaceuticals

Honoraria (Speaker): AstraZeneca, Schering-Plough, Merck

Other Commercial Interests: Director, HealthyAirways, LLC, Vice President, Strategic Pharmaceutical Advisors